Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Sir Dave Stuart, FRS FMedSci, NDM’s Professor of Structural Biology, knighted for services to medical research and the scientific community.

Professor Sir Dave Stuart

Dave is the Founder and Director of the Division of Structural Biology (STRUBI) and Oxford Centre for EM imaging of Infectious Particles (OPIC) and Life Sciences’ Director at the Diamond Light Source. His work ranges across virus-receptor interactions, basic puzzles of virus assembly and studying virus evolution. He has made numerous contributions to the understanding of the structure of viruses, structural vaccinology and anti-viral drug discovery. 

Over the last year, he has led a huge collaborative effort between Diamond, Rosalind Franklin Institute and the University of Oxford studying the structures of SARS-Cov-2 protein structures, and particularly the interaction of the virus’ Spike receptor protein with patient-derived antibodies. This knowledge is being used in anti-COVID19 drug development and tracking and evaluating the significance of new variants. All this work draws heavily on national and international collaborations with academic and industrial partners. Dave has also helped to develop and establish the high-throughput anti-COVID19 antibody screening platform in NDM, which is used by the Office of National Statistics to screen the UK population.

Similar stories

Leedham Lab receives funding to improve bowel cancer treatments

The Leedham Lab at the Wellcome Centre for Human Genetics in the Nuffield Department of Medicine (NDM) has been awarded over £2m from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from Nuffield Department of Medicine's Jenner Institute has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

New study provides important insights into TB correlates of protection

Researchers from the Nuffield Department of Medicine’s Jenner Institute have today reported the findings from a study investigating whether previously identified correlates of protection associated with the risk of tuberculosis (TB) disease could also be associated with the risk of infection from the bacteria that causes TB.

Therapeutic HIV vaccine achieves encouraging results

A phase I/IIa clinical trial that the Nuffield Department of Medicine's Jenner Institute collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.

Prof James Naismith elected as Academy of Medical Sciences' Vice President

Established in 1998, the Academy of Medical Sciences is one of the four UK National Academies, coordinating scholarly research activities and standards in the UK.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.